ASCP 2022 Pathology Symposium

Gain expert insights from a team of oncology pathologists on the rationale for and optimal approach to testing for NTRK and RET genomic alterations in the treatment of lung and thyroid cancer.

Share

Program Content

Activities

  • Thyroid Cancer: Biomarker Testing
    Overview, Rationale, and Guidance on Testing for Rare Genomic Alterations in Advanced Thyroid Cancer
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2022

  • Lung Cancer: Biomarker Testing
    Overview, Rationale, and Guidance on Testing for Rare Genomic Fusions in NSCLC
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 14, 2022

Faculty

cover img faculity

Juan C. Hernandez-Prera, MD

Associate Member
Department of Pathology
Section Head
Head & Neck - Endocrine Pathology
Department of Pathology
Moffitt Cancer Center
Tampa, Florida

cover img faculity

Jeremy P. Segal, MD, PhD

Associate Professor
Department of Pathology
Director
Molecular and Cytogenetic Pathology
University of Chicago
Chicago, Illinois

Provided by

ProCE Banner

Supporters

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group

Lilly

Partners

American Society for Clinical Pathology

ProCE Banner